BCR/ABL1ΔE7‐8‐9 isoform contributes to tyrosine kinase inhibitor resistance in chronic myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

BCR/ABL1ΔE7‐8‐9 isoform contributes to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Published:2022-06-17 Issue:5 Volume:40 Page:1067-1075
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Tan Yanhong¹,Zhang Lingli¹,Zhu Guiyang¹,Yang Yuchao¹,Guo Wenzheng¹,Chen Lanhui¹,Chang Jianmei¹,Xu Yang¹,Muyey Daniel Muteb¹,Wang Hongwei¹^ORCID

Affiliation:

1. Department of Hematology The Second Hospital of Shanxi Medical University Taiyuan China

Funder

Applied Basic Research Project of Shanxi Province, China

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.3040

Reference43 articles.

1. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

2. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

3. Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

4. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

5. Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP